Novartis’ groundbreaking cancer T-cell therapy CTL019 has won unanimous backing from advisers to the FDA, paving the way for approval in the coming months. There had been concerns that the ...

A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

CAR T-cell expansion and persistence were superior ... Kotecha disclosed relationships with Eisai, Allogene Therapeutics, Exelixis, Novartis, Pfizer, Takeda, and Xencor. Campbell and Tannir ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Despite the powerful cancer-fighting capabilities of treatments based on T cells containing an engineered chimeric antigen receptor (CAR) to fight a patient’s cancer, one key challenge is ...

Global CAR T Cell Therapy Market is estimated to valued at US$ 2.26 Bn in 2022 and expected to exhibit a CAGR of 20.9 % during the forecast period (2022-2030). BURLINGAME, CA, UNITED STATES ...